{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:10:03Z","timestamp":1792710603123,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":850,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A13239"],"award-info":[{"award-number":["A13239"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1093\/annonc\/mdx155","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T03:54:24Z","timestamp":1490932464000},"page":"1508-1516","source":"Crossref","is-referenced-by-count":240,"title":["Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study"],"prefix":"10.1016","volume":"28","author":[{"given":"V.","family":"Conteduca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wetterskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.A.","family":"Sharabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Fernandez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jayaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Romanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Casadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gurioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vazquez-Estevez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gonz\u00e1lez del Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Fernandez-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"M\u00e9ndez-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Santander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.I.","family":"S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gasi Tandefelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wingate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dearnaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Demichelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gonzalez-Billalabeitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx155_bb0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx155_bb0015","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx155_bb0020","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1158\/1078-0432.CCR-11-1712","article-title":"Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas","volume":"17","author":"Taniguchi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx155_bb0025","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx155_bb0030","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-12-3768","article-title":"Noninvasive detection of HER2 amplification with plasma DNA digital PCR","volume":"19","author":"Gevensleben","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx155_bb0035","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","article-title":"Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx155_bb0040","doi-asserted-by":"crossref","first-page":"254ra125","DOI":"10.1126\/scitranslmed.3009448","article-title":"Tumor clone dynamics in lethal prostate cancer","volume":"6","author":"Carreira","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1093\/annonc\/mdx155_bb0045","doi-asserted-by":"crossref","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"312","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1093\/annonc\/mdx155_bb0050","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/bjc.2015.128","article-title":"Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"112","author":"Salvi","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx155_bb0055","doi-asserted-by":"crossref","first-page":"37839","DOI":"10.18632\/oncotarget.9341","article-title":"Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer","volume":"7","author":"Salvi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1093\/annonc\/mdx155_bb0060","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx155_bb0065","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","article-title":"Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer","volume":"2","author":"Wyatt","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1093\/annonc\/mdx155_bb0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdx155_bb0075","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","article-title":"Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors","volume":"21","author":"Chen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx155_bb0080","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx155_bb0085","doi-asserted-by":"crossref","first-page":"e00499","DOI":"10.7554\/eLife.00499","article-title":"Overcoming mutation-based resistance to antiandrogens with rational drug design","volume":"2","author":"Balbas","year":"2013","journal-title":"Elife"},{"key":"10.1093\/annonc\/mdx155_bb0090","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdx155_bb0095","unstructured":"http:\/\/www.cancerresearchuk.org\/prod_consump\/groups\/cr_common\/@fre\/@fun\/documents\/generalcontent\/cr_027486.pdf (6 April 2017, date last accessed)."},{"key":"10.1093\/annonc\/mdx155_bb0100","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx155_bb0105","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/1078-0432.CCR-14-1961","article-title":"Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate","volume":"21","author":"Attard","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdx155_bb0110","first-page":"vi243","article-title":"Early responses to enzalutamide in AR-V7 positive first line metastatic castration-resistant prostate cancer (mCRPC). A prospective SOGUG clinical trial: The PREMIERE study","volume":"27","author":"Grande","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx155_bb0115","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx155_bb0120","series-title":"R. A Language and Environment for Statistical Computing","author":"R Core Team","year":"2015"},{"key":"10.1093\/annonc\/mdx155_bb0125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/sim.1333","article-title":"Methods for categorizing a prognostic variable in a multivariable setting","volume":"22","author":"Mazumdar","year":"2003","journal-title":"Stat Med"},{"key":"10.1093\/annonc\/mdx155_bb0130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdv594","article-title":"A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel","volume":"27","author":"Chi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx155_bb0135","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx155_bb0140","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S1470-2045(15)70033-1","article-title":"Sequencing of agents in castration-resistant prostate cancer","volume":"16","author":"Lorente","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx155_bb0145","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal Chem"},{"key":"10.1093\/annonc\/mdx155_bb0150","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1093\/annonc\/mdx155_bb0155","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer","volume":"33","author":"Scher","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419322550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419322550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/7\/1508\/24169656\/mdx155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:24:20Z","timestamp":1624681460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419322550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0923753419322550"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx155","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}